Back to Authors

Peoples, Michael D

0000-0001-5233-2603

Mayo Clinic

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Citations 1

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, David H. , Kundu, Samrat T. , Fradette, Jared J. , Diao, Lixia , Tong, Pan, Byers, Lauren A. , Wang, Jing , Canales, Jaime Rodriguez, Villalobos, Pamela, Mino, Barbara , Yang, Yanan , Minelli, Rosalba, Peoples, Michael , Bristow, Christopher A. , Heffernan, Timothy P. , Carugo, Alessandro , Wistuba, Ignacio I. , Peoples, Michael D , Gibbons, Don L , Yang, Yanan

Science Translational Medicine | March 13, 2019 | Volume: 11 | Issue: 483 | Pages: No page available

10.1126/scitranslmed.aaq1238 Get It

Suppression of ZEB1 through miR-200 expression or HDAC inhibition with mocetinostat sensitizes resistant KRAS mutant lung cancers to MEK inhibition.